On March 26, the opening ceremony was held, and Xu Qiang, the secretary of the Jinxian County Committee of Jiangxi Province, attended the ceremony and announced the official opening of Jiangxi Tellgen. On the day of the celebration, Xiong Hui, deputy secretary of the Jinxian County Committee and county magistrate, Xu Zhigang, member of the …
Tellgen, March 18, 2023, Shanghai As spring turns and warmth arrives, on March 17th, the “20th Anniversary Forum on the Development of Flow Fluorescence Technology” hosted by Tellgen was successfully held in Beijing, marking the first stop of the annual event. Accompanied by the green tiles and bricks of the ancient capital, the chirping birds …
Tellgen Corporation is the leading company in the IVD industry, which went public in 2017 with a stock code of 300642. Tellgen was established in 2003 and focused on the needs of patients, doctors, and institutions. Tellgen specializes in chemiluminescence immunoassays, multiplexed bead flow fluorescence immunoassays, mass spectrometry, molecular diagnostics, and clinical chemistry.
MORE ABOUT US
Deeper Understanding of Life. We at Tellgen Corporation always focus on the needs of doctors, patients, and institutions. We believe in the power of innovation and devotion.
READ MORE
Tellgen Corporation was established in 2003 at the Medicine Valley in Shanghai, also known as the Silicon Valley of China, which is the first to develop reagents based on Luminex Platforms.
READ MORE
Went public in 2017 in Shenzhen and grew to 800 employees. Patented multiple products like Colon9 and LungMe using DNA methylation technology that changed the game of tumor detection.
READ MORE
The accuracy and number of compatible reagents and testing items unique to the Tellgen and TESMI series are comparable to the international first line, with a promising future.
iKang cooperated closely with the well-known IVD listed company Tellgen Corporation and introduced detection items such as tumor markers and HPV27 genotyping to empower Healthy China.
Accurate diagnosis is the premise of precise medical treatment. As the success of a specific diagnosis, clinical mass spectrometry is opening a new chapter of target medicine.
We, at Tellgen Corporation, are the devoting and innovating people in the IVD industry. We are dedicated to improving the health care and living quality of world citizens.
